A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

NCT02435433 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

399

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Ramucirumab
DRUG: Placebo

Sponsor

Eli Lilly and Company